The Pharma Letter7h
AnaptysBio rockets on rosnilimab data
Shares in AnaptysBio, a San Diego-based biotech focused on delivering innovative immunology therapeutics, was trading 19% ...
Dual-target drug may lead to new treatment approach for breast cancer patients
Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at ...
ENDPOINTS NEWS9h
Anap­tys­Bio gets a mid-stage win for PD-1 drug in rheuma­toid arthri­tis
AnaptysBio trumpeted a Phase 2b success in rheumatoid arthritis Wednesday morning after a similar program from Eli Lilly was discontinued late last year.
FierceBiotech12h
AnaptysBio's PD-1 drug reduces rheumatoid arthritis in phase 2 trial
AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...
manilatimes13h
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
At Week 14, 69% (71% of b/tsDMARD-naïve and 66% of b/tsDMARD-experienced) or 220 of the 318 rosnilimab-treated patients across all doses achieved CDAI LDA and were eligible to remain on continued ...
AnaptysBio announces Phase 2b RENOIR trial met primary endpoint
AnaptysBio (ANAB) announced statistically significant Week 12 data from the global 424-patient Phase 2b RENOIR trial of investigational ...
GlobalData on MSN16h
Health Canada approves MSD’s Keytruda for NSCLC stages
Health Canada has approved MSD's anti-programmed cell death protein 1 (PD-1) therapy Keytruda for treating adults with ...